Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Mental Health is issuing a forecast for a biphasic research opportunity using the R21/R33 activity code to evaluate how HIV immunotherapies affect central nervous system outcomes. The primary objective is to determine if these therapies can safely target HIV persistence in the CNS while reducing neuroinflammation and neurotoxicity. This research will specifically focus on overcoming challenges such as blood brain barrier penetration and compartmentalized viral dynamics to improve long term cognitive and neurologic health for people living with HIV. Managed by the Department of Health and Human Services under the National Institutes of Health, this initiative seeks investigators with specialized expertise in viral reservoirs and CNS impacts. The funding opportunity is designed to generate evidence for achieving sustained virologic remission across all anatomical compartments. Interested parties are encouraged to establish collaborations in preparation for the formal notice of funding opportunity.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Mental Health (NIMH) intends to publish a notice of funding opportunity (NOFO) to solicit biphasic research applications to evaluate the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV and to identify mechanisms, benefits, and risks associated with their use in the CNS compartment. The primary goal is to generate evidence that informs whether HIV immunotherapies can safely and effectively target CNS HIV persistence while minimizing neurotoxicity and neuroinflammation. By addressing CNS-specific barriers such as blood brain barrier penetration, compartmentalized viral dynamics, and immune-mediated effects, this NOFO will support the development of strategies that contribute to sustained virologic remission across anatomical compartments and improve long-term neurologic and cognitive outcomes in people with HIV. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into the impact of HIV immunotherapies on the CNS and viral reservoirs are strongly encouraged to apply to this new NOFO. This NOFO will utilize the R21/R33 activity code.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
